# Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis

> **NCT02929251** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 112 (actual)

## Conditions studied

- Uveitis
- Biotherapy

## Interventions

- **DRUG:** Anakinra
- **DRUG:** Tocilizumab
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT02929251
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-29
- **Primary completion:** 2021-10-29
- **Final completion:** 2022-01-29
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02929251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02929251, "Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02929251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*